Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 8Lymphoid 5Tumor-Agnostic 4Breast 4Head & Neck 3Sarcoma 2Plasma cell 2Other 2Genitourinary 2Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1Endocrine 1Classical hematology 1

Conditions

Vaso-Occlusive Crises 1Anemia, Sickle Cell 1

Interventions

Cyclophosphamide 93fludarabine phosphate 86Busulfan 63Cyclosporine 57Peripheral Blood Stem Cell Transplantation 54Mycophenolic Acid 54Whole-Body Irradiation 53Epoetin Alfa 53Antilymphocyte Serum 43fludarabine 42Filgrastim 41Cytarabine 41Tacrolimus 39Melphalan 38Darbepoetin alfa 38Methotrexate 34Radiotherapy 32Cord Blood Stem Cell Transplantation 28Granulocyte Colony-Stimulating Factor 23Methylprednisolone 21Etoposide 21apixaban 18eltrombopag 16Thiotepa 16Dalteparin 16ferric carboxymaltose 14Daunorubicin 14Azacitidine 14Alemtuzumab 14thymoglobulin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Glutamine × Classical hematology × Clear all
NCT01179217 2020-08-19

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

Emmaus Medical, Inc.

Phase 3 Completed
230 enrolled 19 charts 1 FDA
Classical hematology

Vaso-Occlusive Crises, Anemia, Sickle Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡